BIOMEDIKA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 7,161,353 | 5,241,722 | 4,385,723 | 4,617,327 | 5,611,738 | 7,027,463 | 6,826,887 | 4,424,098 |
| Profit before tax | 418,227 | 714,695 | 707,163 | 702,687 | 1,102,759 | 1,410,543 | 1,312,105 | 534,904 |
| Net profit | 317,505 | 598,588 | 594,034 | 586,009 | 914,158 | 1,173,000 | 1,093,174 | 418,145 |
| Equity | 165,664 | 764,252 | 1,246,498 | 1,747,145 | 2,411,303 | 3,184,303 | 3,777,477 | 3,695,622 |
| Liabilities | 3,282,276 | 2,280,611 | 2,189,645 | 1,310,890 | 1,186,824 | 1,488,499 | 1,400,637 | 1,023,563 |
| Non-current assets | 104,218 | 149,950 | 140,548 | 100,107 | 123,863 | 116,447 | 130,303 | 653,871 |
| Current assets | 3,348,265 | 2,894,362 | 3,291,872 | 2,951,836 | 3,476,416 | 4,563,623 | 5,045,494 | 4,023,262 |
| Total assets | 3,452,483 | 3,044,312 | 3,432,420 | 3,051,943 | 3,600,279 | 4,680,070 | 5,175,797 | 4,677,133 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 906,314 | 935,350 | 528,679 |
| Social insurance contributions | - | - | - | - | - | 175,006 | 198,751 | 181,748 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +44.2% | -26.8% | -16.3% | +5.3% | +21.5% | +25.2% | -2.9% | -35.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 9.2% | 19.7% | 17.3% | 19.2% | 25.4% | 25.1% | 21.1% | 8.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 191.7% | 78.3% | 47.7% | 33.5% | 37.9% | 36.8% | 28.9% | 11.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.4% | 11.4% | 13.5% | 12.7% | 16.3% | 16.7% | 16.0% | 9.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.8% | 13.6% | 16.1% | 15.2% | 19.7% | 20.1% | 19.2% | 12.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 19.8 | 3.0 | 1.8 | 0.8 | 0.5 | 0.5 | 0.4 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 246,236 | 353,375 | 292,382 | 313,039 | 352,569 | 390,415 | 403,559 | 262,818 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
BIOMEDIKA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-20 | 0.01 |
| 2024-03-22 | 2024-04-07 | 0.13 |
| 2024-03-18 | 2024-03-20 | 0.19 |
| 2023-11-16 | 2023-11-19 | 110.56 |
BIOMEDIKA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-10 | 2024-12-12 | 1891.25 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
BIOMEDIKA, UAB, a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods, reported revenue of €4.42M in 2025. Net profit was €418.1K, with a profit margin of 9.5%. Performance weakened year on year, as revenue fell 35.2% from 2024 and was 37.0% below the 2023 level. The three-year trajectory shows a decline from €7.03M in 2023 to €6.83M in 2024 and then to €4.42M in 2025, while net profit moved from €1.17M to €1.09M and then to €418.1K. At year-end 2025, total assets stood at €4.68M, equity at €3.70M and liabilities at €1.02M. The company maintained a strong equity position, with an equity ratio of 79.0% and debt-to-equity of 0.28. Asset turnover was 0.95x, ROE was 11.3% and ROA was 8.9%. Revenue per employee was €276.5K, with profit per employee of €26.1K.